
Prostate Cancer
Oxford University Press
2nd Edition
Published on 24. June 2010
Book
Paperback/Softback
120 pages
978-0-19-957393-6 (ISBN)
Description
Around 32,000 men in the UK are diagnosed with prostate cancer each year. It differs from most other cancers in the body, in that small areas of cancer within the prostate are very common and may not grow or cause any problems for many years. It is often it is diagnosed during a routine checkup so most men that are diagnosed often have no warning signs.
About one in three men over the age of 50 have some cancer cells within their prostate and nearly all men over the age of 80 have a small area of prostate cancer. It may cause pain, difficulty in urinating, erectile dysfunction and other symptoms, but early prostate cancer usually causes no symptoms.
Since the first edition of this book was published in 2003, there have been several groundbreaking studies completed that have changed the way that certain categories of the disease are treated. This new edition of the book includes sections on radiotherapy, which is now known to be an effective treatment for men with residual prostate cancer after surgery, and a heavily updated chapter on Advanced Disease.
About one in three men over the age of 50 have some cancer cells within their prostate and nearly all men over the age of 80 have a small area of prostate cancer. It may cause pain, difficulty in urinating, erectile dysfunction and other symptoms, but early prostate cancer usually causes no symptoms.
Since the first edition of this book was published in 2003, there have been several groundbreaking studies completed that have changed the way that certain categories of the disease are treated. This new edition of the book includes sections on radiotherapy, which is now known to be an effective treatment for men with residual prostate cancer after surgery, and a heavily updated chapter on Advanced Disease.
More details
Series
Edition
2nd Revised edition
Language
English
Place of publication
Oxford
United Kingdom
Target group
Patients and their families, GPs, nurses and associated healthcare professionals
Edition type
Revised edition
Product notice
Paperback (trade)
Unsewn / adhesive bound
Illustrations
Various 2-colour line drawings and halftones
Various 2-colour line drawings and halftones
Dimensions
Height: 193 mm
Width: 127 mm
Thickness: 13 mm
Weight
136 gr
ISBN-13
978-0-19-957393-6 (9780199573936)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions

Malcolm Mason | Leslie Moffat
Prostate Cancer
E-Book
06/2010
2nd Edition
OUP eBook
€10.49
Available for download

Malcolm Mason | Leslie Moffat
Prostate Cancer
E-Book
06/2010
2nd Edition
OUP eBook
€10.49
Available for download
Previous edition

Book
09/2003
Oxford University Press
€22.32
Article exhausted; check for reprint
Persons
Professor Malcolm Mason is an Oncologist with a special interest in prostate cancer. He has been closely involved in clinical trials in prostate cancer for the Medical Research Council for over 18 years, and he has had a research programme in Cardiff University into this disease since 1997. He qualified in London at St Bartholomew's Hospital, and trained in Oncology at the Royal Marsden Hospital, London. He moved to Cardiff in 1992. He is also past-Chairman of the British Prostate Group.
In 2009, Professor Mason was appointed the Chairman of the National cancer Research Institute's Prostate Cancer Clinical Studies Group, the main UK group responsible for developing and overseeing clinical trials in prostate cancer in the UK.
Mr Leslie Moffat trained in Edinburgh and Glasgow. He published the largest study of LHRH analogues Chairman of Scottish Urological Cancer Audit, the largest of its kind in the world.
In 2009, Professor Mason was appointed the Chairman of the National cancer Research Institute's Prostate Cancer Clinical Studies Group, the main UK group responsible for developing and overseeing clinical trials in prostate cancer in the UK.
Mr Leslie Moffat trained in Edinburgh and Glasgow. He published the largest study of LHRH analogues Chairman of Scottish Urological Cancer Audit, the largest of its kind in the world.
Author
Cancer Research Wales Professor of Clinical Oncology, Cardiff University
Consultant Urological Surgeon and Honorary Senior Lecturer, University of Aberdeen
Content
1. Introduction ; 2. How do doctors measure the severity and extent of a prostate cancer? ; 3. Risks and benefits of screening and radical treatment - a guide ; 4. Treatment and management options ; 5. Screening ; 6. Hormone therapy ; 7. Locally Advanced Disease ; 8. Advanced Disease ; 9. Alternative treatments ; 10. Chemo prevention and vitamins ; 11. Clinical Trials ; 12. Prostate cancer and sex ; 13. Questions and answers ; Glossary ; Sources of information